The latest price target for Keros Therapeutics (NASDAQ:KROS) was reported by Cantor Fitzgerald on January 21, 2025. The analyst firm set a price target for $0.00 expecting KROS to fall to within 12 months (a possible -100.00% downside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for Keros Therapeutics (NASDAQ:KROS) was provided by Cantor Fitzgerald, and Keros Therapeutics downgraded their neutral rating.

There is no last upgrade for Keros Therapeutics

The last downgrade for Keros Therapeutics Inc happened on January 21, 2025 when Cantor Fitzgerald changed their price target from N/A to N/A for Keros Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Keros Therapeutics (KROS) is trading at is $11.64, which is out of the analyst’s predicted range.